Safety and Tolerability of PCSK9 Inhibitors: Current Insights

Constantine E Kosmas,1 Andreas Skavdis,2 Andreas Sourlas,3 Evangelia J Papakonstantinou,4 Edilberto Peña Genao,5 Rogers Echavarria Uceta,5 Eliscer Guzman1 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA; 2School of Medicine, University of Athens,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kosmas CE, Skavdis A, Sourlas A, Papakonstantinou EJ, Peña Genao E, Echavarria Uceta R, Guzman E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	hypercholesterolemia cardiovascular disease cvd pcsk9 inhibitors safety tolerability. Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/817a135acf6143918c3328e778e3ad40
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:817a135acf6143918c3328e778e3ad40
record_format	dspace
spelling	oai:doaj.org-article:817a135acf6143918c3328e778e3ad402021-12-02T15:12:04ZSafety and Tolerability of PCSK9 Inhibitors: Current Insights1179-1438https://doaj.org/article/817a135acf6143918c3328e778e3ad402020-12-01T00:00:00Zhttps://www.dovepress.com/safety-and-tolerability-of-pcsk9-inhibitors-current-insights-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Constantine E Kosmas,1 Andreas Skavdis,2 Andreas Sourlas,3 Evangelia J Papakonstantinou,4 Edilberto Peña Genao,5 Rogers Echavarria Uceta,5 Eliscer Guzman1 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA; 2School of Medicine, University of Athens, Athens, Greece; 3School of Medicine, University of Crete, Heraklion, Greece; 4General Directorate of Public Health and Social Welfare, Attica Region, Athens, Greece; 5Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USACorrespondence: Constantine E Kosmas 168-24 Powells Cove Blvd., Beechhurst, NY 11357, USATel +1-646-734-7969Email cekosmas1@gmail.comAbstract: The current era of preventive cardiology continues to emphasize on low-density lipoprotein cholesterol (LDL-C) reduction to alleviate the burden of atherosclerotic cardiovascular disease (ASCVD). In this regard, the pharmacological inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme via monoclonal antibodies has emerged as a novel lipid-lowering therapy, leading to a marked reduction in circulating LDL-C levels and subsequent improvement of cardiovascular outcomes. As these agents are increasingly used in current clinical practice, mounting scientific and clinical evidence supports that PCSK9 inhibitors offer an excellent safety and tolerability profile with a low incidence of adverse events. Notably, the most frequently reported side effects are injection-site reactions. In contrast to statins, PCSK9 inhibitors do not appear to exert a detrimental effect on glycemic control or to increase the incidence of new-onset diabetes mellitus. Accumulating evidence also indicates that PCSK9 inhibitors are a safe, well-tolerated and effective therapeutic strategy for patients with statin intolerance. On the other hand, as PCSK9 inhibitors reduce LDL-C to unprecedented low levels, a large body of current research has examined the effects of their long-term administration on neurocognition and on levels of vitamin E and other fat-soluble vitamins, providing encouraging results. This review aims to present and discuss the current clinical and scientific evidence pertaining to the safety and tolerability of PCSK9 inhibitors.Keywords: hypercholesterolemia, cardiovascular disease, CVD, PCSK9 inhibitors, safety, tolerabilityKosmas CESkavdis ASourlas APapakonstantinou EJPeña Genao EEchavarria Uceta RGuzman EDove Medical Pressarticlehypercholesterolemiacardiovascular diseasecvdpcsk9 inhibitorssafetytolerability.Therapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 12, Pp 191-202 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	hypercholesterolemia cardiovascular disease cvd pcsk9 inhibitors safety tolerability. Therapeutics. Pharmacology RM1-950
spellingShingle	hypercholesterolemia cardiovascular disease cvd pcsk9 inhibitors safety tolerability. Therapeutics. Pharmacology RM1-950 Kosmas CE Skavdis A Sourlas A Papakonstantinou EJ Peña Genao E Echavarria Uceta R Guzman E Safety and Tolerability of PCSK9 Inhibitors: Current Insights
description	Constantine E Kosmas,1 Andreas Skavdis,2 Andreas Sourlas,3 Evangelia J Papakonstantinou,4 Edilberto Peña Genao,5 Rogers Echavarria Uceta,5 Eliscer Guzman1 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA; 2School of Medicine, University of Athens, Athens, Greece; 3School of Medicine, University of Crete, Heraklion, Greece; 4General Directorate of Public Health and Social Welfare, Attica Region, Athens, Greece; 5Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USACorrespondence: Constantine E Kosmas 168-24 Powells Cove Blvd., Beechhurst, NY 11357, USATel +1-646-734-7969Email cekosmas1@gmail.comAbstract: The current era of preventive cardiology continues to emphasize on low-density lipoprotein cholesterol (LDL-C) reduction to alleviate the burden of atherosclerotic cardiovascular disease (ASCVD). In this regard, the pharmacological inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme via monoclonal antibodies has emerged as a novel lipid-lowering therapy, leading to a marked reduction in circulating LDL-C levels and subsequent improvement of cardiovascular outcomes. As these agents are increasingly used in current clinical practice, mounting scientific and clinical evidence supports that PCSK9 inhibitors offer an excellent safety and tolerability profile with a low incidence of adverse events. Notably, the most frequently reported side effects are injection-site reactions. In contrast to statins, PCSK9 inhibitors do not appear to exert a detrimental effect on glycemic control or to increase the incidence of new-onset diabetes mellitus. Accumulating evidence also indicates that PCSK9 inhibitors are a safe, well-tolerated and effective therapeutic strategy for patients with statin intolerance. On the other hand, as PCSK9 inhibitors reduce LDL-C to unprecedented low levels, a large body of current research has examined the effects of their long-term administration on neurocognition and on levels of vitamin E and other fat-soluble vitamins, providing encouraging results. This review aims to present and discuss the current clinical and scientific evidence pertaining to the safety and tolerability of PCSK9 inhibitors.Keywords: hypercholesterolemia, cardiovascular disease, CVD, PCSK9 inhibitors, safety, tolerability
format	article
author	Kosmas CE Skavdis A Sourlas A Papakonstantinou EJ Peña Genao E Echavarria Uceta R Guzman E
author_facet	Kosmas CE Skavdis A Sourlas A Papakonstantinou EJ Peña Genao E Echavarria Uceta R Guzman E
author_sort	Kosmas CE
title	Safety and Tolerability of PCSK9 Inhibitors: Current Insights
title_short	Safety and Tolerability of PCSK9 Inhibitors: Current Insights
title_full	Safety and Tolerability of PCSK9 Inhibitors: Current Insights
title_fullStr	Safety and Tolerability of PCSK9 Inhibitors: Current Insights
title_full_unstemmed	Safety and Tolerability of PCSK9 Inhibitors: Current Insights
title_sort	safety and tolerability of pcsk9 inhibitors: current insights
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/817a135acf6143918c3328e778e3ad40
work_keys_str_mv	AT kosmasce safetyandtolerabilityofpcsk9inhibitorscurrentinsights AT skavdisa safetyandtolerabilityofpcsk9inhibitorscurrentinsights AT sourlasa safetyandtolerabilityofpcsk9inhibitorscurrentinsights AT papakonstantinouej safetyandtolerabilityofpcsk9inhibitorscurrentinsights AT penagenaoe safetyandtolerabilityofpcsk9inhibitorscurrentinsights AT echavarriaucetar safetyandtolerabilityofpcsk9inhibitorscurrentinsights AT guzmane safetyandtolerabilityofpcsk9inhibitorscurrentinsights
_version_	1718387641064357888

Safety and Tolerability of PCSK9 Inhibitors: Current Insights

Ejemplares similares